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Abstract
Human phthalate exposure is ubiquitous, but little is known regarding predictors of urinary
phthalate levels. To explore this, 50 pregnant women aged 18–38 years completed two
questionnaires on potential phthalate exposures and provided a first morning void. Urine samples
were analyzed for 12 phthalate metabolites. Associations with questionnaire items were evaluated
via Wilcoxon tests and t-tests, and r-squared values were calculated in multiple linear regression
models. Few measured factors were statistically significantly associated with phthalate levels.
Individuals who used nail polish had higher levels of mono-butyl phthalate (p=0.048) than non-
users. Mono-benzyl phthalate levels were higher among women who used eye makeup (p=0.034)
or used makeup on a regular basis (p=0.004). Women who used cologne or perfume had higher
levels of di-(2-ethylhexyl) phthalate metabolites. Household products, home flooring or paneling,
and other personal care products were also associated with urinary phthalates. The proportion of
variance in metabolite concentrations explained by questionnaire items ranged between 0.31 for
mono-ethyl phthalate and 0.42 for mono-n-methyl phthalate. Although personal care product use
may be an important predictor of urinary phthalate levels, most of the variability in phthalate
exposure was not captured by our relatively comprehensive set of questionnaire items.
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Introduction
Phthalates are synthetic diesters of phthalic acid used in a variety of industrial and consumer
products. High molecular weight phthalates are added to plastics to enhance flexibility and
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durability. Low molecular weight phthalates are used in adhesives, detergents, and solvents.
Sources of phthalate exposure in consumer products are varied and include polyvinyl
chloride (PVC) plastics, building materials, medical devices, pharmaceuticals, automotive
components, toys, food packaging, cosmetics, fragrances, and pesticides (Schettler, 2006).
Biomonitoring studies have demonstrated ubiquitous human exposure to phthalates in the
developed world. Three phthalate metabolites, mono-ethyl, mono-n-butyl, and mono-benzyl,
were present in more than 97% of urinary samples analyzed in the 1999–2000 National
Health and Nutrition Examination Survey (NHANES) (Silva et al., 2004).
Widespread phthalate exposure has prompted investigations of their potential adverse health
effects. Fetal exposures are of particular concern because phthalate metabolites cross the
placenta and have been measured in amniotic fluid (Silva et al., 2004), placental tissue
(Mose et al., 2007), cord blood (Latini et al., 2003), and neonatal meconium (Kato et al.,
2006). Experimental animal studies have reported adverse reproductive and developmental
effects and suggest that phthalates may have endocrine-disrupting properties (Lyche et al.,
2009). Human in utero exposure has been linked to altered gestational duration, reduced
anogenital distance in boys, and impaired behavior and executive functioning skills (Adibi et
al., 2009; Engel et al., 2010; Latini et al., 2003; Swan et al., 2005; Swan, 2008; Whyatt et
al., 2009; Wolff et al., 2008). Reproductive, respiratory, metabolic, and thyroid effects in
children and adults have also been reported (Bornehag and Nanberg, 2010; Duty et al., 2003;
Hatch et al., 2008; Hauser et al., 2006; Huang et al., 2007; Stahlhut et al., 2007).
Phthalates are quickly metabolized and excreted in urine, with elimination half lives of less
than 24 hours (Koch et al., 2005). Urinary biomarkers are widely used to assess human
exposure. However, biomarkers represent total exposure and cannot differentiate the
contribution of particular exposure sources or routes. Several studies have assessed the
correlation between urinary biomarkers of phthalate exposure and specific consumer
products, such as baby care items, medical devices and medications, foods, fragrances, and
personal care products (Adibi et al., 2003; Berman et al., 2009; Calafat et al., 2004; Colacino
et al., 2010; Duty et al., 2005; Hernandez-Diaz et al., 2009; Just et al., 2010; Kwapniewski
et al., 2008; Romero-Franco et al., 2011; Sathyanarayana et al., 2008). These previous
studies provide evidence that urinary biomarkers incorporate phthalate exposure from
various consumer products. However, none have quantified the degree to which urinary
phthalate levels can be explained by consumer product exposure. The aim of this project was
to design a questionnaire to predict urinary phthalate exposures in a population of pregnant
women, who have a greater potential risk of adverse effects.
Materials and Methods
Population
The parent study for this phthalate exposure assessment project was the Right From the Start
(RFTS) study, a geographically-based, prospective study of the relationship between tap
water disinfection byproducts and spontaneous pregnancy loss. Women in three U.S. cities
who were in early pregnancy (less than 12 weeks gestation) or who were trying to become
pregnant were recruited by advertisement, direct mailing, pregnancy test coupons, and
referrals from prenatal care sites. Interested women were screened by telephone for
eligibility. The study was conducted from 2000 to 2004 and is described elsewhere
(Hoffman et al., 2008; Promislow et al., 2004; Savitz et al., 2006).
A subcohort of women from each of the three RFTS sites was recruited for the phthalates
protocol. Included women were approximately gestational weeks 22–24, did not use assisted
reproductive technology to conceive, had a singleton gestation, intended to carry the
pregnancy to term, were 18 years of age or older, and had, at minimum, conversational
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English skills. The women also had to have completed a first-trimester study ultrasound by
10 weeks estimated gestational age. Women eligible for the phthalate subcohort completed a
detailed mailed questionnaire prior to their baseline study visit, and were mailed materials to
collect a first morning urine specimen on the day of their visit. Participants completed a 48-
hour recall questionnaire during the baseline study visit. Demographic data were obtained
during the RTFS screening call.
Questionnaires
The mailed questionnaire was designed to capture information on a variety of potential
phthalate exposures including housing characteristics, building materials, cleaning products,
cosmetics, prepared food, fragrances, and medical equipment. Questions focused on
ascertaining potential phthalate exposure in the past year. The 48-hour recall questionnaire
contained yes/no questions about exposures in the past 48 hours, including home
renovations, chemicals, cosmetics, personal care items, nail care, and medical exposures.
This questionnaire also included four global questions aimed at determining whether
participants regularly wore makeup, used cosmetics or household products that contain
fragrance, ate prepackaged foods or foods prepared at fast food restaurants, or did cleaning
that involved using household cleaners at least 2 hours per week.
Biological Samples
First morning void urine samples were divided into 3.0 ml aliquots, stored at −20°C and
shipped frozen to the Centers for Disease Control and Prevention for analysis. Urine
samples were analyzed for phthalate monoesters and creatinine using methods described
previously (Blount et al., 2000). Specifically, mono-butyl phthalate (MBP), mono-benzyl
phthalate (MBZP), mono-cyclohexyl phthalate (MCHP), mono-ethyl phthalate (MEP),
mono-ethylhexyl phthalate (MEHP), mono-n-methyl phthalate (MMP), mono-isononyl
phthalate (MINP), monon-octyl phthalate (MOP), mono-(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono-isobutyl phthalate
(MIBP), and mono-3-carboxypropyl phthalate (MCPP) were measured. Samples were
spiked with 13C4-labeled phthalate monoesters and 4-methylumbelliferone glucuronide.
They were then treated with β-glucuronidase to release the phthalate monoesters from their
conjugated forms. Deconjugated urine samples were extracted twice with Oasis HLB solid
phase extraction and resuspended in mobile phase. Chromatographic separation by high
pressure liquid chromatography was followed with tandem mass spectrometry on a triple
quadrupole instrument using atmospheric pressure chemical ionization (Finnigan Inc., San
Jose, CA). Levels of 4-methylumbelliferone were monitored as quality control for the
deconjugation step. Method blanks, laboratory quality control samples (spiked human urine)
and standards were analyzed along with the study urine samples. Urinary creatinine was
measured using an ASTRA analyzer (Beckman Inc., Brea, CA) based on a Jaffe rate
reaction. Samples were analyzed in batches and at least one quality assurance sample and
one duplicate were included in each batch. These quality assurance samples and duplicates
were labeled and handled in an identical manner to actual samples with the laboratory
unaware of sample status.
Statistical Analysis
Fifty women from May 2002 through September 2003 contributed both complete
questionnaire and urinary phthalate data for the analyses. Observations below the limit of
detection (LOD) were assigned a value of half the detection limit. Phthalate concentrations
are reported as the absolute concentration in urine (ng/ml) and the concentration adjusted for
urinary creatinine (μg/g creatinine) to account for urine dilution. Phthalate levels were
divided by the creatinine level and then multiplied by 100 to obtain creatinine-adjusted
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levels. MBZP and MEP levels were corrected for inaccurate phthalate standards in place at
the time of laboratory analysis (multiplied by 0.66 and 0.72, respectively).
To evaluate associations between urinary phthalate concentrations and product use
questionnaire responses, mean natural log transformed creatinine-adjusted phthalate levels
were compared using Satterthwaite T tests. If a phthalate's distribution was not log-normal,
median creatinine-adjusted phthalate levels were compared with Wilcoxon rank-sum tests.
Statistical significance was determined at an alpha level of 0.05.
We also assessed the proportion of variance in phthalate metabolite levels explained by
items in the two questionnaires. This analysis was conducted in two stages in order to screen
a large number of items and obtain a parsimonious model. In the first stage, the association
between each log creatinine-adjusted phthalate metabolite and questionnaire item was
assessed in a bivariate linear regression model. In the second stage, items with p<0.1 in the
bivariate models were entered into multiple linear regression models for each phthalate and
the proportion of variance explained (R2) was computed. This analysis was limited to
metabolites detected in >70% of samples, and the di-(2-ethylhexyl) phthalate (DEHP)
metabolites MEHHP, MEHP, and MEOHP were examined as a molar sum (ΣDEHP).
Significance was evaluated at an alpha level of 0.1 in order to include all important
predictors of phthalate metabolite levels in the multiple regression models. All analyses
were conducted using SAS version 9.2 (Cary, NC) and only questionnaire items reported by
at least 5 women were assessed.
Results
Characteristics of this sample of pregnant women are described in Table 1. Women were
predominantly white or black non-Hispanic, never smokers, and had at least some college
education. Phthalate concentrations with and without creatinine-adjustment are reported in
Table 2. Urinary levels of MCHP, MINP, and MOP were below the limits of detection for
all or nearly all women. Creatinine-adjusted phthalate distributions were log-normal except
for MBP and MBZP; thus, results for these two metabolites are presented as medians rather
than arithmetic means. Median phthalate levels reported in this study are comparable to U.S.
population levels but lower than levels among pregnant women estimated by the National
Health and Nutrition Examination Survey (NHANES) during a similar time period (Table
3).
Frequencies of product use reported on the 48-hour recall and mailed questionnaires and
their associations with phthalate metabolites are reported in Tables 4 and 5, respectively.
Products most commonly used by women in the past 48 hours were makeup and personal
care items, particularly eye makeup, lipstick, and hand creams or lotions.
Women who reported using makeup most days of the week had higher levels of MBZP than
women who did not (medians: 10.4 vs 5.2 μg/g creatinine, p=0.004). Use of eye shadow,
eyeliner, or mascara in the past 48 hours was associated with higher levels of MBP
(medians: 26.3 vs 12.8 μg/g creatinine, p=0.013), MBZP (medians: 7.9 vs 5.2 μg/g
creatinine, p=0.034), MIBP (means: 3.7 vs 1.4 μg/g creatinine, p=0.022), and MEOHP
(means: 23.6 vs 15.4 μg/g creatinine, p=0.045). Sunscreen use in the past 48 hours was
associated with higher levels of MBP (medians: 50.7 vs 15.2 μg/g creatinine, p=0.024) and
MMP (means: 3.2 vs 1.6 μg/g creatinine, p<0.001). Women who reported using bath oil,
bath gel, or bubble bath in the past 48 hours had higher levels of MMP (means: 2.2 vs 1.5
μg/g creatinine, p=0.009). Using hair nutrient products in the past 48 hours was associated
with increased urinary levels of MEP (means: 136.5 vs 124.7 μg/g creatinine, p=0.036) and
MMP (means: 2.9 vs 1.6 μg/g creatinine, p=0.002). Women who applied or removed nail
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polish in the past 48 hours had statistically significantly higher levels of MBP (medians:
30.2 vs 15.1 μg/g creatinine, p=0.048) than women who were not exposed to nail polish. In
contrast, urinary MEP concentrations were statistically significantly lower among women
who applied or removed nail polish (means: 33.2 vs 138.7 μg/g creatinine, p=0.002).
Women who normally tried to buy fragrance-free products had lower levels of both MEHP
(means: 6.8 vs 17.4 μg/g creatinine, p=0.037) and its secondary phthalate metabolite,
MEHHP (means: 14.4 vs 37.6 μg/g creatinine, p=0.032). Use of cologne or perfume was
associated with higher levels of MIBP (means: 3.6 vs 2.0 μg/g creatinine, p=0.011) and the
DEHP metabolites MEHP (means: 17.2 vs 8.1 μg/g creatinine, p=0.007), MEHHP (means:
36.7 vs 18.1 μg/g creatinine, p=0.007), and MEOHP (means: 26.3 vs 13.8 μg/g creatinine,
p=0.011).
Few women reported using household chemicals or cleaning products in the 48-hour recall
questionnaire. In the mailed questionnaire, regular fabric softener use was associated with
higher levels of MEP (means: 176.7 vs 95.0 μg/g creatinine, p=0.039). Air freshener use
was associated with higher levels of MBP (medians: 23.9 vs 8.9 μg/g creatinine, p=0.015),
MBZP (medians: 8.9 vs 3.5 μg/g creatinine, p=0.003), and MEP (means: 147.7 vs 70.7 μg/g
creatinine, p=0.026).
With the exception of three items on the mailed questionnaire, housing characteristics and
building materials were not associated with urinary metabolite levels. Women who lived in a
building with two or more units had higher levels of MIBP (means: 4.7 vs 2.5 μg/g
creatinine, p=0.018) than women who lived in a house. Women who had vinyl flooring in
their places of residence had significantly lower levels of MEHP (means: 8.6 vs 22.0 μg/g
creatinine, p=0.016). Paneling in the home was associated with higher levels of MEP
(means: 201.4 vs 113.8 μg/g creatinine, p=0.026).
Eating deli or “to go” foods three or more times a week was not associated with phthalate
levels in this group of women. Analyses could not be completed on IV treatments or
chemical products such as paints and solvents because our sample of women did not report
exposure to these items. There were no statistically significant associations between
consumer products and MCPP, MEOHP, or MMP.
The results of our exploratory analysis of predictive ability of the questionnaire variables are
presented in Table 6. The R2 values ranged between 0.31 for MEP and 0.42 for MMP. To a
large extent, the predictors associated with each of the phthalates were personal care
products, although different products were associated with different phthalates. While these
models explained more variance than individual variables, there was no compelling pattern
to the predictors identified. MMP had six products which overall explained 42% of the
variance in creatinine adjusted MMP levels. Four of the products (sunscreen, bath oil, hair
nutrient products, and hair styling gel) were positively associated with MMP, while two
(spot cleaners and lipstick) were inversely associated. For MBP, seven items explained 39%
of the variance and all were positively associated; four of these were personal care products
used within the past two days and three where regular home activities within the past year
(regular use of dryer sheets, air fresheners, and having interior walls painted).
Discussion
In this sample of pregnant women, questionnaire items related to product use were
associated with urinary levels of some phthalate metabolites. Current use of personal care
products and regular use of cleaning products in the home were associated with urinary
phthalate concentrations. None of the four global questions about makeup, fragrance-free
products, food, or household cleaners nor any of the specific product items explained
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substantial variability in phthalate levels on their own. Given the complex patterns of
exposure to phthalates, these analyses suggest that questionnaires are unlikely to predict
urinary phthalate levels to an extent that would be adequate in epidemiologic studies of
health effects.
The majority of pregnant women in this sample reported using makeup and personal care
products. Because many of these products contain phthalates, frequent exposure may result
in consistently elevated phthalate concentrations during pregnancy. In the current study,
three personal care products were associated with higher levels of MMP: bath oil, bath gel,
or bubble bath; hair nutrient products; and sunscreen. In other investigations of phthalate
exposure sources, MMP was associated with baby lotion and shampoo in one study
(Sathyanarayana et al., 2008), but was not significantly associated with personal care
products in another (Duty et al., 2005). Although three prior studies reported increased
urinary levels of MEP among those using personal care products or lotion (Berman et al.,
2009; Romero-Franco et al., 2011; Sathyanarayana et al., 2008), the only positive
association we observed for MEP was use of hair nutrient products in the past 48 hours.
Mono-benzyl phthalate, which was anticipated to correlate with questions about plastic
materials, was associated with using eye makeup in the last 48 hours and using makeup most
days of the week. Other studies of personal care products have not reported positive
associations with mono-benzyl phthalate.
In this study, the dibutyl phthalate metabolite MBP was positively associated with nail
polish use. Dibutyl phthalate is an integral part of nail polishes (Koo and Lee, 2004).
Occupational studies of phthalate exposure in manicurists have reported increased
concentrations of dibutyl phthalate metabolites (Hines et al., 2009; Kwapniewski et al.,
2008) and a previous study of phthalate exposure among pregnant women reported that nail
polish use was associated with increased levels of dibutyl phthalate metabolites (Hines et al.,
2009). We also observed an inverse association between MEP and applying or removing
nail polish in the past 48 hours. Previous literature does not support this finding, which may
have occurred by chance.
In our sample, MEP was positively associated with air freshener use but no other aspect of
fragrance use or avoidance. MEP is the phthalate metabolite thought to be most associated
with fragrances (Koo and Lee, 2004) and this finding is in contrast to two prior studies that
reported dose dependent increases in urinary MEP levels with perfume, cologne, or
aftershave use (Duty et al., 2005; Just et al., 2010). DEHP metabolites were positively
associated with cologne or perfume use and inversely associated with buying fragrance-free
products; DEHP has also been detected in perfumes (Koo and Lee, 2004). The association
with DEHP but not MEP may reflect differences in the phthalate content of particular
products and brands used by the women in this sample compared to other populations
studied.
We used first morning voids to measure phthalate concentrations as these have been shown
to be reliable and reproducible over time (Hoppin et al., 2002). While the variability in first
morning voids is less than for spot urine samples, our study may have been unable to detect
an association between phthalate metabolites and personal care products due to their short
half lives and lack of product application prior to the first morning void. This may explain
why we do not see associations with MEP that others have seen. By using first morning
voids, we may have collected lower levels of MEP than other studies. Indeed, the median
MEP concentration in our sample (61 ng/mL) was lower than reported by the Duty et al. (96
ng/mL, standard-corrected) and Just et al. (131 ng/mL, standard-corrected) studies.
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Phthalates are a primary component of PVC plastics. The amount of PVC used in floor and
wall materials has been reported to correlate with benzyl butyl phthalate and DEHP levels in
house dusts (Bornehag et al., 2005). Adibi et al. reported significant correlations between
dust phthalate levels and urinary concentrations of MEP, MBP, and MBZP, demonstrating
that inhalation may be an important exposure route (Adibi et al., 2003). While we observed
positive associations between MIBP and living in a building with two or more units and
between MEP and paneling in the home, there were no positive associations between
plastic-containing materials in the home and DEHP metabolites. Contrary to expectations,
living in a home with vinyl flooring was inversely associated with DEHP metabolites. One
possible explanation for this finding is that homes without vinyl flooring may have been
dustier, resulting in higher phthalate exposure via indoor air. Alternatively, this finding may
be due to confounding if women with vinyl flooring in their homes had lower exposure to
other sources of DEHP. The ability to detect associations with housing characteristics may
also have been limited by our small sample size. Furthermore, dust phthalate levels may be a
better metric for internal exposure to phthalates from plastics in housing materials than
questionnaire data on the presence of PVC or vinyl materials in the home (Bornehag et al.,
2005).
The proportion of variance in urinary phthalate metabolite levels explained by models
including multiple product use items was moderate (R2 = 0.31 – 0.42). These results suggest
that a detailed questionnaire ascertaining the use of phthalate-containing products may have
utility in predicting levels of some phthalate metabolites. However, the variation not
explained by items on our questionnaires was substantial, indicating that major predictors of
phthalate levels were not ascertained. It is therefore unlikely that these questionnaires could
be used to classify phthalate exposures with enough discrimination for use in epidemiologic
studies.
The consumer product questionnaires designed for this study aimed to capture potential
phthalate exposures from home, cosmetic, medical, and cleaning product sources. However,
we were unable to assess medical product or recent chemical use in relation to urinary
phthalate levels because no women in our sample reported these exposures. Although
comprehensive with respect to known phthalate sources, the questionnaires may not have
ascertained information on important phthalate-containing products. Food is thought to be a
primary exposure source due to the use of phthalates in packaging (Schettler, 2006). An
analysis of urinary phthalate levels in relation to dietary intake in NHANES reported
positive associations between DEHP and DEP metabolites and consumption of poultry and
vegetables, respectively (Colacino et al., 2010). There was no association in our study
between phthalate concentrations and eating deli or to go foods, which may be due to the use
of first morning voids because exposure is unlikely to occur prior to sample collection. In
addition, more detailed questionnaire data would be necessary for a full characterization of
dietary phthalate exposure. More research on the phthalate content of foods would improve
the ability to construct useful questionnaire items.
Phthalate metabolite concentrations were lower in this study than among pregnant women in
NHANES, which may represent differences in exposures detectable by spot urine samples
versus first morning voids. Because phthalates have a short half life and exposures are
unlikely to occur within 8–10 hours prior to first morning voids, phthalate exposures may be
underestimated in this sample limiting our ability to identify associations with product use.
The small number of women in this sample limits the power to detect differences between
product users and nonusers. Thus, questionnaire items that were significantly different
between groups represent strong associations. It is also possible that some of the
associations observed in the t-test comparisons are due to chance or to confounding, because
the results of this analysis are unadjusted. Estimates of the proportion of variance explained
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by questionnaire items were unable to support a large number of variables and may not have
included all important predictors. The results of this study may not be generalizable to non-
pregnant women due to differences in physiology and product use during gestation.
Correlations between questionnaire responses and phthalate levels were based on a single
urine sample from each woman. Phthalate half lives are short with reproducibility of urinary
phthalate metabolite levels measured on consecutive days ranging from 0.5 to 0.8,
depending on the phthalate (Hoppin et al., 2002). Studies examining repeated urine samples
over periods of up to 3 months reported intraclass correlations between 0.2 and 0.8,
indicating that a single sample may be useful to project long term exposure to some
phthalates but not others (Adibi et al., 2008; Fromme et al., 2007; Hauser et al., 2004;
Marcus et al., 2010). Although creatinine is highly variable during pregnancy, the use of
first morning voids collected during a short window of gestation (weeks 22–24) minimizes
the potential bias from creatinine adjustment.
Use of questionnaire data for exposure assignment in epidemiologic studies of phthalates
and health effects may be problematic for several reasons. Questionnaires are complicated to
design and administer and they require open ended options to capture information on brands
and products. Exposure sources are numerous and it may not be possible to construct a
questionnaire that is able to ascertain all important sources of exposure. Finally, phthalate
levels in products change over time and product labeling is not required in the United States,
further limiting the ability to link specific products and exposure levels.
Conclusion
This study characterized usage of phthalate-containing products among a sample of pregnant
women and assessed associations with urinary phthalate metabolites. The findings suggest
that application of personal care products may be an important predictor of urinary phthalate
levels; however, the metabolites associated with questionnaire items were not always the
phthalates that were anticipated. Using these two detailed questionnaires we were able to
explain more of the variance in urinary phthalate levels than by using one question alone,
but it is unclear how consistent these predictors will be over time. The major predictors of
urinary phthalate levels in pregnant women have yet to be identified.
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Table 1
Demographic characteristics of the 50 pregnant study participants, 2000–2004
Characteristic n (%)
Maternal Age (years)
 18–24 8 (16)
 25–29 16 (32)
 30–34 20 (40)
 35+ 6 (12)
Race
 White 23 (46)
 Black 20 (40)
 Other 7 (14)
Hispanic
 Yes 6 (12)
 No 44 (88)
Education
 High school or less 7 (14)
 Some college 14 (28)
 College or more 29 (58)
Income
1
 ≤$40 000 13 (26)
 $4 001–$80 000 21 (42)
 > $80 000 12 (24)
Maternal BMI (kg/m2)
1
 < 24.9 24 (48)
 25–29.9 15 (30)
 30+ 10 (20)
Smoking Status
1
 Never 34 (68)
 Former 8 (16)
 Current 0 (0)
Total number of pregnancies
1
 1 9 (18)
 2 18 (36)
 3+ 21 (42)
Total number of births
1
 0 16 (32)
 1 21 (42)
 2+ 11 (22)
1
Numbers do not sum to 50 due to missina values.
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Table 3
Comparison of median creatinine-adjusted urinary phthalate levels (μ/g creatinine) to a U.S. population-based
sample
Phthalate Present study (n = 50) NHANES
1
 total population (n = 2 782) NHANES
2
 pregnant women (n = 111)
MBP 17.9 17.4 22.7
MBZP
3 7.7 9.7 15.7
MCHP 0.1 < LOD
MCPP 1.2 2.5 3.5
MEHHP 18.7 16.6 22.8
MEHP 5.3 3.9 10.4
MEOHP 14.0 11.2 17.8
MEP
3 68.7 98 306.4
MIBP 1.6 2.5 3.3
MINP 0.4 < LOD
MMP 1.3 1.3 2.1
MOP 0.5 < LOD 0.7
1
Data from the 2001–2002 National Health and Nutrition Examination Survey (NHANES) (Centers for Disease Control and Prevention, 2010).
2
Data from the 2001–2002 National Health and Nutrition Examination Survey (NHANES) (Ye et al., 2009).
3
NHANES levels for MBZP and MEP are standard-corrected. < LOD Below limit of detection
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Table 6
Multiple linear regression results and proportion of variance explained (R2) for urinary phthalate metabolites
and product use questionnaire items
1
Phthalate Questionnaire item Regression coefficient Standard error R2
MBP Intercept 1.37 0.36 0.39
Sunscreen (last 2 days) 0.74 0.45
Other cream or lotion (last 2 days) 0.30 0.32
Eye shadow, liner, or mascara (last 2 days) 0.20 0.31
Applied or removed nail polish (last 2 days) 0.42 0.36
Dryer sheets regularly used (last 12 months) 0.32 0.32
Air freshener (last 12 months) 0.63 0.33
Walls painted (last 12 months) 0.40 0.27
MBZP Intercept 0.76 0.39 0.32
Makeup most days of the week (global item) 0.44 0.41
Eye shadow, liner, or mascara (last 2 days) 0.20 0.41
Applied or removed nail polish (last 2 days) 0.07 0.47
Air freshener (last 12 months) 1.35 0.40
Laminate flooring in home (last 12 months) 0.43 0.45
MEP Intercept 3.83 0.27 0.31
Fabric starch (last 2 days) 0.89 0.36
Fabric softener regularly used (last 12 months) 0.36 0.28
Air freshener (last 12 months) 0.66 0.30
Paneling in home (last 12 months) 0.78 0.40
MMP Intercept 0.57 0.39 0.42
Spot cleaners (last 2 days) −0.77 0.33
Sunscreen (last 2 days) 0.45 0.49
Bath oil, bath gel, or bubble bath (last 2 days) 0.67 0.31
Lipstick, chapstick, or lip balm (last 2 days) −1.25 0.40
Hair nutrient product (last 2 days) 0.82 0.44
Hair styling gel, mousse, pomade, or grease (last 2 days) 0.59 0.30
ΣDEHP2 Intercept 3.08 0.47 0.34
Try to buy fragrance free products (global item) −0.45 0.31
Eye shadow, liner, or mascara (last 2 days) 0.54 0.29
Cologne or perfume (last 2 days) 0.50 0.31
Air freshener (last 12 months) 0.45 0.30
Vinyl or linoleum floors in home (last 12 months) −0.40 0.31
1
Multiple linear regression models for each phthalate include questionnaire items statistically significant at p<0.1 in bivariate linear regression
models
2
Molar sum of the DEHP metabolites MEHHP, MEHP, and MEOHP
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